Oral Antibiotics Market Expected to Reach $28.8 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Oral Antibiotics Market," The oral antibiotics market size was valued at $22.5 billion in 2022, and is estimated to reach $28.8 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032. The oral antibiotics market trends which are driven the growth of the market including the high prevalence of bacterial infections across the globe. Bacterial infections are a significant burden on public health, affecting individuals of all age groups. Antibiotics are effective against a wide range of bacterial pathogens, thus playing a crucial role in the treatment of these infections. In addition, the growth in population and increase in healthcare expenditure have contributed to the growth of the oral antibiotics market. The incidence of bacterial infections increases, leading to a greater demand for antibiotics with an expanding population which creates an oral antibiotics market opportunity.

In addition, the availability of generic antibiotic medications is a significant driver contributing to the oral antibiotics market growth. Generic antibiotic medications are typically more affordable than their brand-name counterparts. This cost advantage makes them an attractive option for healthcare providers, insurers, and patients. The availability of affordable generic options increases accessibility to antibiotic treatment, particularly in regions with limited healthcare resources or populations with financial constraints. This affordability factor drives the demand for generic oral antibiotics and expands the growth during oral antibiotics market forecast. 

For instance, Teva Pharmaceuticals Limited provides a variety of generic antibiotic products that serve as alternatives to branded medications. These include Amoxicillin Capsules USP, Amoxicillin for Oral Suspension USP, Amoxicillin Tablets USP, and Amoxicillin Tablets USP (Chewable). These generic products are designed to be equivalent to the brand Amoxil, which is manufactured by GlaxoSmithKline plc. Thus, by offering these generic versions, Teva Pharmaceuticals Limited contributes to the growth of the oral antibiotic market by expanding the availability and accessibility of oral antibiotics, which drives the market growth. 

However, factors that restrain the market growth include the rise of antibiotic resistance, stringent regulatory requirements, adverse effects, and safety concerns associated with certain antibiotics, and the increase in preference for non-antibiotic alternatives. In addition, the availability of over-the-counter medications and self-medication practices is expected to hinder market growth by reducing the need for prescription antibiotics.

On the basis of class, the beta-lactam & beta-lactamase inhibitors segment held the highest oral antibiotics market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period owing to its broad-spectrum activity and effectiveness against a wide range of bacteria. However, bacteria develop resistance to beta-lactams by producing beta-lactamase enzymes that break down these antibiotics. Beta-lactamase inhibitors, such as clavulanic acid and sulbactam, are combined with beta-lactam antibiotics to enhance their efficacy, for overcoming this resistance mechanism.

However, the quinolone segment is expected to witness the highest CAGRs during the forecast period, owing to an increase in the prevalence of resistant bacteria, a diverse range of use Indications such as respiratory tract infections, urinary tract infections, gastrointestinal infections, and skin and soft tissue infections.

On the basis of the spectrum of activity, the broad-spectrum antibiotic segment held the highest oral antibiotics market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period, it is attributed to versatility, effectiveness, and strategic importance of broad-spectrum antibiotics in the treatment of various infections, especially in the face of increasing antibiotic resistance.

On the basis of application, the Urinary tract infections (UTIs) segment held the highest market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period, as it is the most common hospital-acquired infection accounting for almost 40% of all nosocomial infections and females are more inclined to acquire UTI every year as compared to males.

However, the community-acquired respiratory tract infections (CARTIS) segment is expected to witness the highest CAGRs during the forecast period, owing to the high prevalence of community-acquired respiratory tract infections, the need for effective treatments due to antibiotic resistance, ongoing R&D, demographic factors and improved healthcare access.

On the basis of drug origin, the semisynthetic segment held the highest market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms. 

However, the synthetic segment is projected to exhibit the highest CAGR in the oral antibiotic market during the forecast period, owing to the rise in the need for synthetic membrane-targeted antibiotics due to antimicrobial resistance. Synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and a low probability of developing resistance.

On the basis of drug type, the branded segment held the highest market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period. Brand recognition, R&D investments, strong patent protection, physician prescribing patterns, and effective marketing strategies contribute to the sustained market share and revenue generation of branded oral antibiotics.

However, the generic segment is projected to exhibit the highest CAGR in the oral antibiotics market size during the forecast period, this is attributed to the fact that it offers a more affordable option compared to its branded counterparts. In addition, regulatory agencies in various countries have established pathways and regulations to encourage the development and approval of generic medications.

North America held the highest market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period. Several factors contribute to this market including an increase in the incidence of infectious bacterial diseases and the presence of guidelines for optimizing the use of antibiotics. In addition, the presence of key market players and their offerings strengthens the market position. These companies actively engage in R&D, ensuring the availability of innovative and effective penicillin drugs in the market. 

However, the Asia-Pacific region is projected to exhibit the highest CAGR during oral antibiotics market analysis. This growth is attributed to several factors, owing to the large number of antibiotics consumption, easy availability of antibiotics, and rise in sales of antibiotics without prescription. Furthermore, the high prevalence of infectious diseases remains a significant driver for the demand for oral antibiotics.

Key findings of the study  
• On the basis of class, the beta-lactam & beta-lactamase inhibitors segment dominated the oral antibiotics industry in terms of revenue in 2022. However, the quinolone segment is anticipated to grow at the fastest CAGR during the forecast period.  
• On the basis of application, the Urinary tract infections (UTIs) segment held the largest market share in 2022 . However, the Community-acquired respiratory tract infections (CARTIS) segment is anticipated to grow at the fastest CAGR during the forecast period.    
• On the basis of the spectrum of activity, the Broad-spectrum antibiotic segment dominated the oral antibiotics industry in terms of revenue in 2022 and is expected to remain dominant throughout the forecast period.
• On the basis of drug origin, the semisynthetic segment dominated the market in terms of revenue in 2022. However, the synthetic segment is anticipated to grow at the fastest CAGR during the forecast period.   
• On the basis of drug type, the branded segment held the largest market share in 2022. However, the generic segment is anticipated to grow at the fastest CAGR during the forecast period  
• On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.